Poslechněte si podcast Few & Far Between: Conversations from the Front Lines of Drug Development

Episode 54, Part One: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics	Few & Far Between: Conversations from the Front Lines of Drug Development	45:11
Episode 53: Frank David, Founder and Managing Director, Pharmagellan	Few & Far Between: Conversations from the Front Lines of Drug Development	50:46
Episode 52: Joshua Kresh, Emily Michiko Morris, and Mark Schultz, IPPI	Few & Far Between: Conversations from the Front Lines of Drug Development	52:05
Episode 51: Dan Oliver, CEO and Founder, Rejuvenate Bio	Few & Far Between: Conversations from the Front Lines of Drug Development	55:05
Epsiode 50: Jonathan Rigby, Chairman and CEO, Sernova	Few & Far Between: Conversations from the Front Lines of Drug Development	52:02
Episode 49: Eileen Faucher, Principal and Founder, Brass Tacks Health	Few & Far Between: Conversations from the Front Lines of Drug Development	35:37
Episode 48: John Celebi, President and CEO, Sensei Bio	Few & Far Between: Conversations from the Front Lines of Drug Development	38:46
Episode 46: Ben Olds and Amy Fenollosa, Haven Human Asset Ventures	Few & Far Between: Conversations from the Front Lines of Drug Development	43:29
Episode 47 - Marc Lajoie, CEO at Outpace Bio	Few & Far Between: Conversations from the Front Lines of Drug Development	48:25
Episode 46: Dr. Carsten Rudolph, CEO and Managing Director at Ethris	Few & Far Between: Conversations from the Front Lines of Drug Development	37:26
Episode 44: Jonathan Scheiman, PhD, Co-Founder and CEO at FitBiomics	Few & Far Between: Conversations from the Front Lines of Drug Development	44:29
Episode 43: Isaac Stoner, Co-founder and CEO at Octagon Therapeutics	Few & Far Between: Conversations from the Front Lines of Drug Development	39:18
Episode 42: Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent Biomedical	Few & Far Between: Conversations from the Front Lines of Drug Development	36:14
Episode 41: Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health	Few & Far Between: Conversations from the Front Lines of Drug Development	35:24
Episode 40: Professor Justin Stebbing, Editor-in-Chief, Oncogene journal	Few & Far Between: Conversations from the Front Lines of Drug Development	33:23
Episode 39: Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center	Few & Far Between: Conversations from the Front Lines of Drug Development	45:10
Episode 38: Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School	Few & Far Between: Conversations from the Front Lines of Drug Development	38:27
Episode 37: Will Greene, Prader-Willi Syndrome patient advocate, Healthcare Engagement Lead at Roche	Few & Far Between: Conversations from the Front Lines of Drug Development	41:31
Episode 36: Zak Kohane, Department of Biomedical Informatics at Harvard Medical School	Few & Far Between: Conversations from the Front Lines of Drug Development	51:43
Episode 35: Charlene Son Rigby, CEO at Global Genes	Few & Far Between: Conversations from the Front Lines of Drug Development	44:55
Episode 34: Dan Mandell, CEO at GRO Biosciences	Few & Far Between: Conversations from the Front Lines of Drug Development	44:45
Episode 33: Diana Sims-Silbermann, Clinician and Former Senior Trial Manager at Janssen Pharmaceuticals	Few & Far Between: Conversations from the Front Lines of Drug Development	26:33
Episode 32: Stephanie Wisner, Author, Co-Founder at Centivax	Few & Far Between: Conversations from the Front Lines of Drug Development	37:05
Episode 31: Pam Cusick, SVP, Rare Patient Voice	Few & Far Between: Conversations from the Front Lines of Drug Development	44:32
Episode 30, Part Two: Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH	Few & Far Between: Conversations from the Front Lines of Drug Development	35:12
Episode 30, Part One: Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH	Few & Far Between: Conversations from the Front Lines of Drug Development	45:07
Episode 29: Mika Newton, CEO at XCures	Few & Far Between: Conversations from the Front Lines of Drug Development	46:50
Episode 28: Dr. Alok Tayi, Founder and CEO of VibeBio	Few & Far Between: Conversations from the Front Lines of Drug Development	30:48
Episode 27, Part 2: Jamie Heywood, Biotech Engineer and Entrepreneur	Few & Far Between: Conversations from the Front Lines of Drug Development	38:55
Episode 27, Part 1: Jamie Heywood, Biotech Engineer and Entrepreneur	Few & Far Between: Conversations from the Front Lines of Drug Development	33:36
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.	Few & Far Between: Conversations from the Front Lines of Drug Development	39:02
Episode 25: Jim Geraghty, Author and Biotech Industry Veteran	Few & Far Between: Conversations from the Front Lines of Drug Development	39:44
Episode 24: Gadi Lachman, President and CEO, TriNetX	Few & Far Between: Conversations from the Front Lines of Drug Development	39:58
Episode 23: Dr. Arun Bhatt, Consultant for Clinical Research and Drug Development in India	Few & Far Between: Conversations from the Front Lines of Drug Development	37:26
Episode 22: Dr. Jocelynn Pearl, Senior Scientist at Tune Therapeutics, Host of Lady Scientist Podcast	Few & Far Between: Conversations from the Front Lines of Drug Development	23:58

Episode 54, Part One: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics

Few & Far Between: Conversations from the Front Lines of Drug Development

45:11

Episode 53: Frank David, Founder and Managing Director, Pharmagellan

Few & Far Between: Conversations from the Front Lines of Drug Development

50:46

Episode 52: Joshua Kresh, Emily Michiko Morris, and Mark Schultz, IPPI

Few & Far Between: Conversations from the Front Lines of Drug Development

52:05

Episode 51: Dan Oliver, CEO and Founder, Rejuvenate Bio

Few & Far Between: Conversations from the Front Lines of Drug Development

55:05